The Global Human Recombinant Insulin Market, by Product Type (Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting
Human Insulin, Long-Acting Human Insulin, and Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra, Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) was valued US$ 27.4 billion in 2018, and is projected to exhibit a CAGR of 7.2% over the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.
Long-acting insulins (insulin detemir [Levemir[R]], insulin glargine [Lantus[R]]), and intermediate-acting
insulin (NPH insulin) are used to provide basal insulin (Freeland, 2016).
So a pragmatic way of NMB managment might be an algorithm-guided reversal of intermediate-acting
NMBA with sugammadex and neostigmine using quantitative neuromuscular monitoring devices.
Mattoo et al carried out an open label, multicenter, randomized, cross-over study comparing insulin lispro Mix25 [25% short-acting lispro/75% intermediate-acting
lispro protamine] and human insulin 30/70 [30% short-acting soluble human insulin/70% intermediate acting NPH]) , in participants with type 2 diabetes, who chose to fast during Ramadan.
If a patient's health condition requires chronic use of glucocorticoids, intermediate-acting
glucocorticoids are recommended to be used every second day to avoid potential complications.
* If insulin is prescribed, the type of insulin (short-, long-, or intermediate-acting
) may depend on how long it takes a person's body to absorb insulin.
The human insulin market report estimates the market size (Revenue USD million - 2013 to 2020) and composition of this market in terms of five product classes such as slow-acting, fast-acting, long-acting, intermediate-acting
and premixed insulin and forecasts growth trends (CAGR% - 2016 to 2020).
Generally utilized as a basal insulin, NPH is a synthetic human insulin that should be considered as intermediate-acting
because of its shorter duration of action compared with the basal Insulin analogs.
In this report, the global human insulin market is segmented on the basis of basis of products (human insulin biologics, insulin analogs & biosimilars, and delivery devices), drug type (rapid-acting, intermediate-acting
, long-acting, short-acting, and premixed), drug brand (Lantus, NovoRapid/Novolog, Humalog, Humulin, Insuman, Actrapid, Insulatard, Mixtard, and Other Biosimilar Brands), delivery devices [insulin pens (reusable & disposable), pen needles (standard & safety), and conventional syringes], and applications (type I diabetes & type II diabetes).
When studies using intermediate-acting
NMBDs were analyzed, the incidence of TOF <0.7 was 12% and TOF<0.9 was 41%.